Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant viral vectors for use in gene therapy, has reported an insider sell transaction by its President and CEO, Kenneth Mills. According to a recent SEC Filing, the insider sold 15,000 shares of the company on February 14, 2024.
Over the past year, Kenneth Mills has sold a total of 105,000 shares and has not made any purchases of the company's stock. The insider transaction history for Regenxbio Inc shows a pattern of more insider selling than buying, with 0 insider buys and 3 insider sells over the past year.
On the date of the recent sell, shares of Regenxbio Inc were trading at $16.76, resulting in a market capitalization of $827.489 million. The company's stock is currently assessed as Fairly Valued with a price-to-GF-Value ratio of 0.92, based on a GuruFocus Value of $18.21.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at Regenxbio Inc, which may be of interest to investors monitoring insider behaviors.
The GF Value image provides a visual representation of the stock's current valuation in relation to its intrinsic value estimate, as calculated by GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
